Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as a loss-making company. None of the usual models had enough data, so this uses Net asset value instead.
ACCE opinionCaribou Biosciences Inc. Common Stock (CRBU)
Fair value
Not available
ACCE price target
$0.48
Rating
Not rated
Horizon
12 months
ACCE price target published on 9 Oct 2026, 00:00 CEST.
Price used: $0.53 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net asset value.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
17
out of 100
Analysts
33% buy
6 covering
P/E
0.0x
forward 0.0x
1-year return
-78.8%
Dividend yield
0.00%
Caribou Biosciences Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Caribou Biosciences develops CRISPR-based gene editing platforms for allogeneic (off-the-shelf) cell therapies, including its CB-010 CAR-T program in oncology and CB-011 in multiple myeloma. The platform is the asset: a proprietary editing toolkit that could in principle let one donor cell product serve many patients, a structural advantage over autologous therapies if clinical data hold. The next catalysts are clinical readouts and any partnership milestones, but the company is still burning cash against a revenue base that fell 43.8% in the latest period, with an operating margin of -1690.4%, so the balance sheet and funding runway matter more than the science for the near term. At a $50M market cap the equity prices in a high probability of dilution or restructuring, and the 18/100 score reflects that. The name merits a deeper look only if you have a view on the clinical timeline and the cash runway, since the financials alone do not make the case.